$15 billion biotech stockthere's clearly a wind at the back of this health care company. As a biotech stock that focuses on rare disease gene therapy, BMRN is highly specialized but also has the potential to create highly profitable drugs in categories that others are ignoring. That means it is a likely buyout candidate by a bigger pharmaceutical company looking to fill in some blanks and bolster its growth prospects.